Figure 5. Efficacy of JAK inhibitors in co-culture.

The response of CD19⁺ PDX cells, co-cultured with MSCs (hCD19^-), to increasing concentrations of momelotinib and ruxolitinib, was assessed after four days of culture using flow cytometry. Cells were stained with Brilliant Violet 421 anti-human CD19 antibody, FITC Annexin V, and PI. Viability was calculated relative to vehicle controls. (A) Survival of PDX cells in mono-culture, or PDX/MSC co-culture. Individual samples were tested in duplicate. Bars represent the mean±SEM of two BCR-JAK2, two TERF2-JAK2, one PAX5-JAK2, three JAK2^R683G and two JAK2^wt samples. Cell viability of samples in mono-culture versus co-culture was compared using the independent sample T-test. ^*p≤0.05. (B-C) The effect of 1.5 μM and 3.0 μM momelotinib or ruxolitinib on the viability of PDX cells with JAK2 translocations in mono-culture, or in co-culture with primary MSCs. Mean±SEM of three JAK2 translocated samples is shown. Cell viability of samples was compared using independent sample T-test. ^*p≤0.05.